Dose rate correction in medium dose rate brachytherapy for carcinoma cervix

Area of Science:

• Oncology
• Radiation Oncology
• Medical Physics

Background:

• Cervical cancer treatment often involves external beam radiation therapy combined with brachytherapy.
• Optimizing brachytherapy dose is crucial for balancing treatment efficacy and patient safety.

Purpose of the Study:

• To determine the optimal brachytherapy dose reduction for stage IIB and III cervical cancer patients.
• To evaluate the impact of different dose reduction levels on local control and treatment-related morbidity.

Main Methods:

• Two studies were conducted comparing medium dose rate (MDR) brachytherapy at 220 cGy/h with reduced doses (12.5% and 30%) to point A.
• Study I compared MDR-12.5% and MDR-30% to historical low dose rate (LDR) brachytherapy (3500 cGy at 55-65 cGy/h).
• Study II prospectively randomized patients to MDR-II (30%) or MDR-II (20%) brachytherapy.

Main Results:

• In Study I, MDR-30% and MDR-12.5% showed similar 5-year local control rates (71.7% and 70.5%) compared to LDR (63.4%).
• MDR-12.5% resulted in significantly higher overall and grade III/IV morbidity (58.5% and 12.5%) than LDR (34.9% and 5.3%).
• No significant difference in morbidity was observed between MDR-30% and LDR groups. Study II showed 3-year local control rates of 66.6% for MDR-II (30%) and 74.8% for MDR-II (20%).
• Rectal morbidity correlated significantly with rectal dose (biologically effective dose, BED).

Conclusions:

• A 30% dose reduction in MDR brachytherapy (at 220 cGy/h) is suggested for cervical cancer patients.
• This dose reduction aims to minimize morbidity without compromising local tumor control.
• Radiobiological data supports a 30% dose reduction factor for optimal outcomes.